This modeling study calculates individualized residual risk estimates for patients with early-stage breast cancer and assesses whether defining eligibility based on a minimum residual risk threshold could increase the reliability of clinical trial power calculations.
http://ift.tt/2DCCSUN
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου